XEOMIN Safety Profile in the Treatment of Blepharospasm

Safety vs placebo

Safety was demonstrated in a randomized, double-blind, placebo-controlled trial of XEOMIN® (incobotulinumtoxinA).1,2

  • Most adverse reactions (ARs) were mild or moderate2
  • No patient withdrew from the study due to an AR2

hcp_3.2_treatment_emergent_aes_table_2

*Including blurred vision

Safety was demonstrated in a randomized, double-blind, multicenter trial in subjects previously treated with onabotulinumtoxinA (Botox).3

  • Ptosis (eyelid) was most commonly observed AR3
  • Most ARs were mild or moderate3
  • No patient withdrew from the study due to an AR

hcp_3.2_treatment_emergent_aes_table_3

References

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2015.
  2. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—a randomized trial. Mov Disord. 2011;26(8):1521-1528.
  3. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303-312.